Phenytoin (PHT) is a first-line drug in the treatment of status epilepticus. However, the parenteral PHT formulation is associated with administration difficulties and therefore fosphenytoin (FosPHT), a PHT pro-drug, has been developed. As the peripheral (blood) and central (cerebrospinal fluid [CSF] and brain extracellular fluid [ECF]) kinetic inter-relationship of PHT after i.v. FosPHT administration is unknown we sought to ascertain the relationship and to compare it to that of i.v. PHT. A freely behaving rat model, which allows for the concurrent and temporal sampling of blood (jugular vein), CSF (cisterna magna) and brain ECF (frontal cortex and hippocampus), was used. PHT and FosPHT were administered by i.v. infusion and blood, CSF and microdialysate samples collected at timed intervals up to 6 hours. The pharmacokinetic parameters in plasma of PHT after PHT and FosPHT (30 and 60 mg/kg) administration were indistinguishable. The PHT plasma free fraction (free/total concentration ratio) was 0.25-0.31 and 0.26-0.31 for PHT and FosPHT, respectively. Mean PHT T max values for CSF were 9-13 minutes. The equivalent values in the frontal cortex and hippocampal ECF were 29-34 minutes. C max values increased dose-dependently and were independent of whether PHT or FosPHT was administered. Furthermore the kinetic profiles of PHT for the frontal cortex and hippocampus were indistinguishable suggesting that PHT distribution in the brain is not brain region specific. Thus, overall, the central and peripheral kinetics of PHT are indistinguishable after PHT and FosPHT.
INTRODUCTION
Phenytoin (PHT, Epanutin, Dilantin, Pfizer Ltd) is a first-line drug in the treatment of convulsive status epilepticus 1 . Although after intravenous or intramuscular administration, PHT enters the central nervous system rapidly so that seizure control is prompt and effective, it has numerous undesirable characteristics. Because PHT is poorly soluble, formulation for parental use requires the use of a vehicle of 40% propylene glycol and 10% alcohol adjusted to a pH of 12 with sodium hydroxide. Intravenous administration of this formulation can result in hypotension, cardiac dysrhythmias and decreased pulse rate 2, 3 , which has been attributed to the propylene glycol vehicle 3, 4 .
Consequently, its administration has to be slow so as to avoid these complications 5, 6 . In addition, extravasation tends to cause local soft tissue and vein injury 7, 8 .
In order to overcome these problematic characteristics, fosphenytoin (FosPHT; a disodium salt of 5,5-diphenyl-3-[(phosphonooxy)methyl]-2-4-imidazolidinedione), a phenytoin pro-drug, has been developed (Cerebyx, Pfizer Ltd). Because FosPHT is water soluble, allowing formulation with a more physiologically compatible vehicle, it exhibits a number of advantages over PHT. It has better intravenous fluid compatibility and stability and therefore causes far less cardiovascular, hepatic and renal adverse effects and can be administered at a faster rate. Furthermore, because FosPHT does not have a high pH value, it is associated with far less pain and burning at the infusion site and indeed minimal consequences occur after intravenous infiltration. These characteristics allow for a longer maintenance of intravenous infusion site 9 . FosPHT is also well tolerated when administered intramuscularly 10, 11 .
Because of the extensive use of PHT in the management of epilepsy in general and its use specifically in status epilepticus, along with the fact that it has some unique and peculiar pharmacokinetic characteristics, the central (cerebrospinal fluid [CSF] and extracellular fluid [ECF] ) and peripheral (blood) kinetic inter-relationship of PHT has been extensively studied in both man and in animals [12] [13] [14] [15] [16] . In contrast, kinetic studies of FosPHT have been confined to the blood compartment, primarily in man, although one animal study reported on its blood kinetics after i.p. administration 17 whilst two other studies reported on its blood and whole brain kinetics after i.p. 18 and i.v. administration 19 . The latter study reported that initial whole brain PHT concentrations were lower after FosPHT administration compared to that after equal molar PHT administration and therefore it was suggested that the efficacy of FosPHT might be less compared to that of PHT. However, whole brain drug concentrations do not necessarily reflect drug content at the site of drug action. Therefore, in the present study we investigated the kinetic inter-relationship of PHT in blood (plasma), CSF and brain ECF (frontal cortex and hippocampus) after intravenous administration of PHT and FosPHT in the freely behaving rat.
METHODS

Animals
Male Sprague-Dawley rats weighing 310-390 g (A. Tuck & Son Ltd, Battlesbridge, Essex, UK) were group housed in contiguous cages and fed ad libitum on normal laboratory diet (SDS R and M number 1 expanded, Scientific Dietary Services, Witham, Essex, UK) and water. A 12-hour light:12-hour dark cycle (lights on 06:00 hour) and ambient temperature of 25 • C were maintained. All animal procedures strictly followed Home Office regulations and were performed under the Animal (Scientific Procedures) Act 1986.
Surgical procedures, blood, CSF and microdialysis sampling
Rats were anaesthetised with 2% halothane (Merial Animal Health Ltd, Dublin, Ireland) inhalation. Two surgical procedures were undertaken. In the first, catheters were implanted in the cisterna magna for CSF sampling, and the right jugular vein for blood sampling as previously described 20 . The second procedure involved the implantation of microdialysis probes in both the hippocampus (from bregma 5.6 mm posterior, 5 mm lateral, 8.2 mm ventral) and the frontal cortex (from bregma 2.5 mm anterior, 1.5 mm lateral, 5.5 mm ventral) according to the atlas of Paxinos and Watson 21 . In addition, a catheter was implanted in the right internal jugular vein for blood sampling 22 .
Animals with blood and CSF catheters were investigated as follows: FosPHT (30 or 60 mg/kg PHT equivalents [PEs]; 200 µl/minute) or PHT (30 or 60 mg/kg; 100 µl/minute) were administered by intravenous infusion (infusion took 4 minutes for PHT and half the time for FosPHT). Blood (200 µl) and CSF (20 µl) were sampled via implanted catheters at timed intervals over a 6-hour period (5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes). Blood samples were collected in 0.5 ml polyethylene tubes (Treff AG, Switzerland) containing 10 µl of 0.55 M EDTA pH 14 (dissolved in 3 M sodium hydroxide). The EDTA served to prevent the in vitro conversion of FosPHT to PHT 19 . Plasma and CSF were stored frozen (−70 • C) until analysis for PHT content.
Animals with blood catheters and microdialysis probes were investigated as follows: artificial CSF (CSF composition in mM: NaCl 125, KCl 2.5, MgCl 2 1.18 and CaCl 2 1.26) was perfused through the probes at 2 µl/minute. Dialysate samples (20 µl) were collected at 10-minute intervals for the first 60 minutes, at 15-minute intervals for the subsequent 60-minute period and thereafter at 30-minute intervals for a further 240 minutes. Blood sampling was undertaken and the samples processed as described above.
Microdialysis probe construction and in vitro recovery
Concentric microdialysis probes were prepared as previously described 23 . In vitro probe recovery was determined by placing each microdialysis probe into a beaker containing 24 µM solution of PHT dissolved in artificial CSF and then perfused with artificial CSF at 2 µl/minute. Samples (40 µl) were collected every 20 minutes for 100 minutes and stored at −70 • C until analysis for PHT content.
Measurement of PHT concentration
Plasma (50 µl), CSF (20 µl) or microdialysate (20 µl) were analysed for PHT content by high performance liquid chromatography 24 . The limit of quantification for PHT was 0.5 µmol/l (CV, 10.1%) and the extraction recovery for plasma, CSF and dialysate was 92-103%. The procedure used for the determination of the free non-protein-bound plasma PHT concentrations was the same as for total PHT concentrations except that samples were first filtered through an Amicon Centrifree Micropartition System (Amicon, Stonehouse, UK) using a Sigma 2K15 centrifuge set at 25 • C.
Kinetic and statistical analysis
PHT versus time data for blood were analysed according to a two-compartment model, whereby for CSF and microdialysate a one-compartment model was used. The parameters computed were as follows: area under the concentration versus time curve (AUC) and apparent elimination half-life (t 1/2 ). Time to maximum concentration (T max ) and maximum concentration (C max ) were obtained by direct inspection of the PHT concentration versus time profiles. Pharmacokinetic constants were compared by the Mann-Whitney test and a P-value <0.05 was considered to be statistically significant.
RESULTS
Blood pharmacokinetics
The mean (±SEM) pharmacokinetic constants for PHT after PHT and FosPHT administration are shown in Table 1 . Peak plasma PHT concentrations were Table 1 : Pharmacokinetic constants of PHT in blood, CSF and brain ECF after intravenous administration of PHT and FosPHT (dosage of FosPHT is equivalent of PHT). achieved by the end of intravenous infusion of both PHT and FosPHT. During the subsequent 15 minutes, concentrations rapidly declined, and the decline continued in an exponential manner (Fig. 1a) . The distribution (alpha-phase) t 1/2 values were of the order of 10 minutes and were neither drug nor dose-dependent. PHT C max values increased dose-dependently after administration of both PHT and FosPHT. However, AUC and t 1/2 values increased disproportionately to dose. Thus, doubling the dose of both PHT and Fos-PHT was associated in a threefold increase in terminal t 1/2 values. Overall, the pharmacokinetic parameters for PHT after PHT and FosPHT administration were indistinguishable.
Mean (±SEM)
The free non-protein-bound PHT concentration was determined in plasma during 5-60 minutes after PHT and FosPHT administration. After PHT administration, the free fraction was 0.25-0.31, whilst after Fos-PHT administration it was 0.26-0.31. Values were not dependent on drug formulation administration and were neither dose nor time-dependent.
Neuropharmacokinetics
CSF
The mean (±SEM) neuropharmacokinetic constants for PHT in CSF after PHT and FosPHT administration are shown in Table 1 . PHT was rapidly detectable in CSF after PHT and FosPHT administration. Mean T max values varied between 9 and 13 minutes and were neither dose-nor formulation-dependent. After administration of PHT and FosPHT, C max values increased dose-dependently and subsequently PHT concentration declined exponentially (Fig. 1b) . However, although AUC and t 1/2 values increased disproportionately to dose after PHT administration, as observed in plasma, values increased dose-dependently after Fos-PHT administration. Overall, the pharmacokinetic parameters in CSF were indistinguishable after FosPHT and PHT administration.
By 15 minutes post PHT and FosPHT administration there was a tendency towards equilibration (as measured by a constant CSF/plasma PHT concentration ratio) between the blood and CSF compartments after the administration of both 30 and 60 mg/kg PHT and FosPHT. For PHT administration the CSF/plasma ratio (mean ± SEM) was 0.12 ± 0.005 whilst for Fos-PHT administration it was 0.19 ± 0.013 (P < 0.01, Mann-Whitney test).
Extracellular fluid
The in vitro relative recovery of PHT for all the microdialysis probes was 18 ± 2% (mean ± SEM) at a dialysate flow rate of 2 µl/minute. These data were used to adjust the in vivo ECF concentration data.
The mean (±SEM) PHT neuropharmacokinetics constants in rat brain frontal cortex and hippocampal ECF are shown in Table 1 . The corresponding PHT concentration versus time profiles are shown in Fig. 2 . PHT was detectable at time of first dialysate sample (10 minutes) for both PHT and FosPHT administration. However, peak PHT concentrations were not achieved until after half an hour, then decreased exponentially. AUC and t 1/2 values in frontal cortex were comparable to that in hippocampus and indeed there was no significant difference in these values when PHT and FosPHT administration are compared. However, ECF t 1/2 values were two-fold greater than those observed in blood and CSF.
The ECF/plasma PHT concentration ratio was indistinguishable during the first 30 minutes in both frontal cortex and hippocampus for PHT and FosPHT (60 mg/kg). Subsequently, however, the ratio was higher after FosPHT administration (0.065 ± 0.008 in frontal cortex vs. 0.06 ± 0.007 in hippocampus) compared to that after PHT administration (0.054 ± 0.006 in frontal cortex vs. 0.053 ± 0.005 in hippocampus; P < 0.05, Mann-Whitney test).
DISCUSSION
A rapid and effective therapeutic response is essential in the management of status epilepticus and Fos-PHT has been developed as a PHT pro-drug in this regard. However, an important consideration relates to how the penetration of PHT, derived from Fos-PHT, into the brain site of action compares to that of PHT after the administration of the parenteral formulation, particularly since a recent report has suggested that PHT whole brain tissue concentrations are significantly lower after i.v. FosPHT compared to PHT administration 19 . Therefore, this study was designed to compare the kinetics of PHT in plasma, CSF and brain (frontal cortex and hippocampus) ECF after i.v. administration of PHT and FosPHT. This was achieved by use of a well-validated freely behaving rat model 23 , which uniquely allows concurrent blood and CSF sampling and ECF monitoring.
The pharmacokinetics of PHT in plasma after i.v. PHT and FosPHT are indistinguishable (Table 1) and indeed the concentrations versus time profiles are essentially super-imposable (Fig. 1a) . Furthermore, the classical well-characterised dose-dependent saturation kinetics of PHT was seen after both PHT and Fos-PHT administration, with comparable increases in t 1/2 values 13, [25] [26] [27] (Table 1) .
As in the case of the blood compartment, the kinetics of PHT after PHT and FosPHT in the CSF compartment was indistinguishable. Rapid PHT CSF penetration was observed after the administration of both PHT and FosPHT with T max values of 9-13 minutes (Fig. 1b) . Furthermore, PHT equilibration between the blood and CSF compartments occurred within 15 minutes of administration of both PHT and FosPHT. The dose-dependent increase in CSF concentrations suggests that transport across the blood-brain barrier is not rate limiting over the concentration range observed in this study.
Since some drugs, including PHT, have been reported not to be uniformly distributed within the brain 12, 28 , microdialysis monitoring of ECF in specific brain sites has been used as an appropriate index of drug distribution at putative sites of drug action. In the present study we monitored ECF of the frontal cortex and hippocampal. After PHT or FosPHT administration PHT rapidly appeared in the brain as evidenced by the fact that PHT was detectable in the ECF of both brain regions at time of first sample (10 minutes; Fig. 2 ). Furthermore, not only was there no difference in the kinetic profiles of PHT after PHT and FosPHT administration but also, in addition, there were no brain regional differences as kinetic parameters in the frontal cortex and hippocampus were indistinguishable (Table 1) . It might be expected that T max values in ECF would be shorter than that for CSF but in fact they were longer and indeed this has been observed in a recent study of the antiepileptic drug levetiracetam 24 . The observed difference in T max value is probably, in part, a reflection of methodology in that CSF was directly sampled (and reflects point analysis) whereas ECF was not (and reflects period analysis). Also, the difference may be a consequence of the fact that the blood-CSF barrier via the choroid plexus is different to that of the blood-brain barrier associated with ECF.
Previously, using rat whole brain homogenates, Walton et al. 19 reported that PHT concentrations were significantly greater after i.v. PHT administration compared to i.v. FosPHT administration. Those data are in contrast to the present study where PHT brain (frontal cortex and hippocampal) ECF concentrations were indistinguishable after i.v. PHT and FosPHT administration and emphasises the need to be cautious about whole brain drug data which may not necessarily reflect the pharmacologically relevant drug compartment.
In conclusion, therefore, this study has shown that, at least in the rat, there is no significant difference in the kinetics of PHT in blood, CSF and ECF compartments of the brain frontal cortex and hippocampus when i.v. PHT and i.v. FosPHT are compared. Thus FosPHT can be expected to be pharmacodynamically identical to that of parenteral PHT and indeed at equimolar doses in experimental seizure models, this is in fact the case 17, 29 .
